Searchable abstracts of presentations at key conferences in endocrinology

ea0046p33 | (1) | UKINETS2016

A case report of bicaval stents and inferior vena cava valve implantation to control carcinoid symptoms in order to safely allow surgical valve replacement

Sagar Vandana , Steeds Rick , Doshi Sagar , Shetty Shishir , Shah Tahir

Severe tricuspid regurgitation (TR) leads to a reduction in cardiac output and an increase in the central venous pressure, resulting in secondary organ dysfunction. Surgery for severe TR is a high-risk procedure, particularly in the presence of uncontrolled carcinoid syndrome (CS) symptoms. Replacement of leaking tricuspid valves can lead to reduction in tumour markers and improvement in carcinoid symptoms. Transcatheter valve implantation into the vena cava may be an alternat...

ea0068p7 | Abstracts | UKINETS2019

pNETs (Pancreatic Neuroendocrine tumours) in MEN1 (Multiple Endocrine Neoplasia): a single centre case series

Venkataraman Hema , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Geh Ian , Shetty Shishir , Shah Tahir , Ayuk John

Introduction: MEN1 associated pNETs share a unique profile in comparison to sporadic pNETs. The literature on pNETs in MEN1 is evolving with on-going ambiguities in presentation and management. We present a case series of MEN1 associated pNETs from a tertiary centre of excellence for NETs in the UK.Methods: Institutional NET database was used for retrospective data analysis for all patients with pNETs associated with MEN1.Results: ...

ea0065cc8 | FEATURED CLINICAL CASE POSTERS | SFEBES2019

Well-differentiated grade 3 neuroendocrine tumors (G3NET) – single centre experience from the UK

Venkataraman Hema , Lithgow Kirstie , Smith Stacey , Kemp-Blake Joanne , Vickrage Suzanne , Hughes Simon , Shetty Shishir , Elshafie Mona , Gadvi Rakesh , Kharkhanis Salil , Ayuk John , Geh Ian , Shah Tahir

Introduction: The WHO classification distinguishes G3NET as a separate entity. Literature on G3NETs is limited to case-reports and small case-series. We aimed to characterise G3NETs from a large tertiary centre.Methods: Retrospective analysis from NET database: 2012–2019. All referrals are discussed at a specialist NET-MDT before entry into clinical pathway. Core NET-MDT consists of a radiologist, nuclear-medicine radiologist, histopathologist, spec...

ea0060oc1 | (1) | UKINETS2018

The proinflammatory molecule, VAP-1, is enriched in the stroma of midgut NETs and plaques of carcinoid heart disease valves

Sagar Vandana M , Neil Desley AH , Papakyriacou Pantelitsa , Shah Tahir , Liu Boyang , Hirschfield Gideon , Steeds Richard P , Shetty Shishir , Weston Christopher J

Background: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis and may contribute to fibrotic complications of neuroendocrine tumours (NETs). We studied the VAP-1 expression in midgut NETs, which are associated with desmoplasia, and carcinoid heart disease (CHD), a significant complication of metastatic midgut NETs.Methods: Immunohistochemical analysis of paraffin-embedded midgut NETs and CHD valves were stained for...

ea0105p31 | Poster Presentations | UKINETS2024

Retrospective study evaluating factors influencing cancer recurrence following surgical resection of pancreatic neuroendocrine tumours (PanNETs)

Rehman Zaira , Freeman Emily , Davies Chris , Boyd Alex , Geh Ian , El-Sayed Mohammed , Hughes Simon , Shetty Shishir , Selvaraj Selva , Elshafie Mona , Ayuk John , Dasari Bobby , Shah Tahir

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are the second most common form of pancreatic cancer. Lesions larger than 2 cm are commonly selected for surgical clearance according to the European Neuroendocrine Tumour Society (ENETS) guidelines. In this study, we assessed the variables that may affect recurrence following resection of PanNETs.Methods: All the patients who underwent resection of PanNET over a 5-year periods between 2017 –...

ea0087p9 | Poster Presentations | UKINETS2022

Ocular neuroendocrine tumour metastases – presentation & outcome

Shah Husnain , Roji Mohamad , Ekmekcioglu Ozgul , Ayuk John , Smith Stacey , Khan Zaira , Vickrage Suzanne , Kemp-Blake Joanne , Humphries Sian , Hughes Simon , Diaz-Cano Salvador , Elshafie Mona , Karkhanis Salil , Shetty Shishir , Geh Ian , Shah Tahir

Introduction: Here we present our experience of managing patients with orbital well-differentiated neuroendocrine tumour (NET) metastases.Methods: Six patients were identified from the hospital NET database: four male; two female.Results: Median age at diagnosis of primary NET: 69.5 years (range: 40-74 years). Three patients were alive at time of data capture. Of those who passed away: mean survival from diagnosis of primary NET = ...

ea0072p4 | (1) | UKINETS2020

Telotristat in the management of Carcinoid diarrhoea – real world experience of patients from an ENETs centre of excellence in Neuroendocrine tumours.

Khanna Amardeep , Cianci Nicole , Abbas Shah Husnain , Goel Ashish , Jebril Asma , Chauhan Jessica , Pipe Michelle , Shetty Shishir , Weston Christopher , Venkataraman Hema , Smith Stacey , Vickrage Suzanne , Kemp-Blake Joanne , Shah Tahir

Carcinoid syndrome occurs in 20% patients, presenting with flushing, abdominal pain, diarrhoea, and wheeze and can be challenging to manage. The standard of care for carcinoid syndrome is somatostatin analogues (SSAs) with add-on Creon, codeine and loperamide therapy. Nonetheless, half of patients experience debilitating diarrhoea. Telotristat-ethyl is a peripheral tryptophan-hydroxylase inhibitor approved for treatment of diarrhoea, supported by Phase 3 clinical trials but la...

ea0072p13 | (1) | UKINETS2020

Well-differentiated Gastroenteropancreatic G3 NET: Findings from a large single centre cohort

Lithgow Kirstie , Venkataraman Hema , Hughes Simon , Shah Husnain , Kemp-Blake Joanne , Vickrage Suzanne , Smith Stacey , Humphries Sian , Elshafie Mona , Taniere Philipe , Diaz-Cano Salvador , Dasari Bobby , Almond Max , Ford Sam , Ayuk John , Shetty Shishir , Shah Tahir , Geh Ian

Purpose: Neuroendocrine neoplasms are known to have heterogeneous biological behavior. G3 neuroendocrine tumours (NET G3) are characterized by well-differentiated morphology and Ki67>20%. The prognosis of this disease is understood to be intermediate between NET G2 and neuroendocrine carcinoma (NEC). Clinical management of NET G3 is challenging due to limited data to inform treatment strategies.Methods: We describe clinical characteristics, treatment, an...

ea0105p18 | Poster Presentations | UKINETS2024

Retrospective audit evaluating outcomes in patients post resection for pancreatic neuroendocrine tumours

Davies Christopher , Freeman Emily , Rehman Zaira , Boyd Alexander , Smith Stacey , Roji Mohamad , El-Sayed Mohamed , Hughes Simon , Elshafie Mona , Shetty Shishir , Selvaraj Selva , Karkhanis Salil , Geh Ian , Venkataraman Hema , Ayuk John , Dasari Bobby , Shah Tahir

Background: Pancreatic Neuroendocrine tumours (panNETs) are usually sporadic and non-functioning, but occasionally associated with germ-line mutations causing multiple hereditary endocrinopathies. Small, non-functional lesions may be managed conservatively. For panNETs larger than 2 cm the mainstay of treatment is surgery (2). However, postoperative complications are common and can significantly impact patients’ quality of life. The aim of this audit was to explore postop...